News
HRTX
2.015
-1.23%
-0.025
Weekly Report: what happened at HRTX last week (0707-0711)?
Weekly Report · 2d ago
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
NASDAQ · 07/07 12:50
Weekly Report: what happened at HRTX last week (0630-0704)?
Weekly Report · 07/07 10:54
Weekly Report: what happened at HRTX last week (0623-0627)?
Weekly Report · 06/30 11:00
Weekly Report: what happened at HRTX last week (0616-0620)?
Weekly Report · 06/23 10:53
Heron Therapeutics Holds Annual Stockholders Meeting
TipRanks · 06/18 10:37
Weekly Report: what happened at HRTX last week (0609-0613)?
Weekly Report · 06/16 10:59
Edison, Apple, Oklo, Heron, Fifth Third: Trending by Analysts
TipRanks · 06/14 09:00
This Ryder System Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Benzinga · 06/09 15:23
Heron Therapeutics Price Target Announced at $6.00/Share by HC Wainwright & Co.
Dow Jones · 06/09 11:39
HC Wainwright & Co. Initiates Coverage On Heron Therapeutics with Buy Rating, Announces Price Target of $6
Benzinga · 06/09 11:29
Weekly Report: what happened at HRTX last week (0602-0606)?
Weekly Report · 06/09 11:00
HERON THERAPEUTICS, INC. <HRTX.O>: H.C. WAINWRIGHT INITIATES COVERAGE WITH BUY RATING
Reuters · 06/09 10:11
Heron Therapeutics initiated with a Buy at H.C. Wainwright
TipRanks · 06/09 10:10
U.S. RESEARCH ROUNDUP-Intuitive Surgical, Oracle, Regeneron Pharmaceuticals
Reuters · 06/09 08:09
Weekly Report: what happened at HRTX last week (0526-0530)?
Weekly Report · 06/02 11:07
Weekly Report: what happened at HRTX last week (0519-0523)?
Weekly Report · 05/26 11:07
Weekly Report: what happened at HRTX last week (0512-0516)?
Weekly Report · 05/19 10:58
Weekly Report: what happened at HRTX last week (0505-0509)?
Weekly Report · 05/12 10:59
Biotech Outperformance - Can't Take What's Already Earned
Seeking Alpha · 05/09 09:37
More
Webull provides a variety of real-time HRTX stock news. You can receive the latest news about Heron Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About HRTX
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. It creates and commercializes a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. Its acute care product portfolio includes ZYNRELEF and APONVIE. Its oncology care product portfolio includes CINVANTI and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is an intravenous formulation of a substance P/neurokinin-1 (NK1) receptor antagonist indicated for postoperative nausea and vomiting (PONV). CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is an extended-release 5-HT3 receptor antagonist for the prevention of acute and delayed nausea and vomiting.